title: Which patients benefit the most from the perindopril/amlodipine combination.
abstract: Fixed-dose combinations have been strongly endorsed by European guidelines for first-line and second-line treatment of hypertension. Among recommended combinations, that of an angiotensin-converting enzyme inhibitor and a calcium channel blocker stands out because the mechanisms of action of these two therapeutic classes are complementary, leading to enhanced efficacy. In the large multicentre ASCOT-BPLA trial, treatment based on the combination of amlodipine and perindopril significantly reduced the risk of cardiovascular and all-cause death, stroke, coronary events and procedures, new-onset diabetes, and new-onset renal impairment in a wide range of patients with hypertension and other cardiovascular risk factors, when compared with atenolol/thiazide-based therapy. The perindopril/amlodipine single-pill combination was developed based on guideline recommendations for combination treatment, the indications of each component, and ASCOT-BPLA trial data. Several studies in real-life settings show that a wide range of hypertensive patients, including everyday hypertensives with common risk factors, would benefit from the perindopril/amlodipine combination.
authors.affiliation: Department of Internal Medicine and Arterial Hypertension, Hôpital Avicenne, Bobigny, France. jean-jacques.mourad@avc.aphp.fr
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Mourad
mesh_terms: D017311:Amlodipine / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D020913:Perindopril / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine; D020913:Perindopril